
A Kaiser score > 5 with breast MRI demonstrated a 97 percent sensitivity and 87.9 percent specificity for predicting malignancy in patients with BI-RADS 0 or 4 presentations on mammography and breast ultrasound, according to a new study.
R2 Technology's proprietary mammography CAD has been approved by the FDA for sale with Fischer Imaging's SenoScan TrueView digital mammography system. Fischer plans to integrate R2's ImageChecker technology with SenoScan to support CAD analysis of
R2 Technology's proprietary mammography CAD has been approved by the FDA for sale with Fischer Imaging's SenoScan TrueView digital mammography system. Fischer plans to integrate R2's ImageChecker technology with SenoScan to support CAD analysis of digital mammograms.



